Therapy Areas: Oncology
AnHeart Therapeutics Launches Study to Evaluate AXL inhibitor AB-329 in Metastatic Breast Cancer
19 October 2021 - - US-based biopharmaceutical company AnHeart Therapeutics has launched sponsored research to evaluate AB-329, an AXL inhibitor in metastatic breast cancer, the company said.
Celcuity Forges Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
19 October 2021 - - US-based biotechnology company Celcuity Inc. (NASDAQ: CELC) has forged a clinical trial collaboration with the University of Rochester Wilmot Cancer Center and biopharmaceutical co...
Geneoscopy names new CMO
19 October 2021 - Geneoscopy Inc., a US-based life sciences company, announced on Monday that it has named Haytham Gareer, MD, PhD as its new chief medical officer.Dr Gareer is a trained surgical onco...
Twist Bioscience, the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research
18 October 2021 - - US-based synthetic biology and genomics company Twist Bioscience Corp. (NASDAQ: TWST) has inked an agreement with the Broad Institute for the distribution of a customized next-gene...
First Patient Dosing in a Phase II Study of Tenalisib in Locally Advanced or Metastatic Breast Cancer Patients
18 October 2021 - - Switzerland-based biopharmaceutical company Rhizen Pharmaceuticals AG has commenced dosing in a phase II trial to evaluate Tenalisib (RP6530; isoform selective dual PI3K δ/&g...
Twist Bioscience, the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research
18 October 2021 - - US-based synthetic biology and genomics company Twist Bioscience Corp. (NASDAQ: TWST) has inked an agreement with the Broad Institute for the distribution of a customized next-gene...
Related Headlines

PathAI partners with Roche

SpinaFX Medical names new COO

FDA Approves Merck's Keytruda Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients with Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2, in Patients with Advanced Solid Tumors

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

Abalos Therapeutics Completes series A Extension Bringing Total Raised to EUR 43m

FDA Approves Merck's Keytruda Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients with Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

Tizona Initiates Phase 1b Expansion Study of TTX-080 in Advanced Refractory or Resistant Malignancies

Tentarix Biotherapeutics Emerges with USD 50m Series A

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin's Lymphoma

Cantargia receives positive EMA opinion for orphan designation of nadunolimab in pancreatic cancer

Eli Lilly's Verzenio(R) (abemaciclib) and endocrine therapy combination gains US FDA breast cancer treatment approval

Eli Lilly wins FDA approval of Verzenio for treatment of HR+ HER2- high risk early breast cancer

Lucid Diagnostics prices IPO at USD14.00 per share

Kiromic BioPharma Forges Strategic Collaboration with Gemelli Teaching Hospital to Accelerate the Analysis of Allogeneic CAR-T Clinical Trial Candidate Alexis ISO-1 in Solid Cancers